Twice-Yearly Depemokimab Improves Peak Expiratory Flow and Asthma Symptoms (Pharmacy Times) - Nov 19, 2025 - "The findings indicated that depemokimab was associated with greater improvements in least squares mean change from baseline in morning PEF compared with placebo from week 1 to 2 (18.08 [95% CI, 14.16–22.01] vs 9.07 [95% CI, 3.65–14.48] L/min, respectively), with an overall treatment difference of about 9.02 (95% CI, 2.31–15.72). Of note, improvement was sustained until weeks 51 to 52 (23.66 [95% CI, 17.64–29.67] vs 7.81 [95% CI, 0.54–16.16], respectively), with a treatment difference of about 15.84 (95% CI, 5.54–26.15)."
P3 data • Asthma
|